semaglutide and heat What Happens If Gets Warm: Storage Safety Guide Efficacy of pharmacotherapies in improving

Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder

Additional information on risks and uncertainties can be found in the Companys Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Companys SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar)

[1] [2] As of 2024, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed medicine in the UK

A mouse model for kinesin family member 11 (Kif11)-associated familial exudative vitreoretinopathy